Evaluation of cardiac and infectious parameters in bone marrow transplant patients

Hematopoietic stem cell transplantation (HSCT) is the process of delivering progenitor stem cells to the patient. It is the therapeutic choice for various malignant and non-malignant diseases. Prior to HSCT, patients are treated with mobilization regimens. These mobilization regimens can be myeloablative, non-myeloablative or reduced-dose. Complications can develop after HSCT. Among the most common complications are those of cardiac origin, which can be seen at all 3 stages of the treatment (acute, subacute or chronic), and can include heart failure (HF). The cardiovascular side effects of the mobilization regimens and cytoreductive therapies can be cumulative. The anthracycline chemotherapeutics, in particular, may have severe cardiac side effects. In our study, 428 HSCT patients (allogeneic or autologous) were analyzed. In both groups, pre-transplant EF values were similar (median: 60%). An increase of more than 10% in post-transplant EF was observed in 2 allo-HSCT (4.4%) and 2 autologous HSCT (3.3%) patients. Among the patients who had more than 25 mmHg increase in pulmonary artery pressure (PAP) post-HSCT, the 5-year survival was decreased significantly (P<0.05).